Onyx Biotec Ltd
ONYX NSE
Onyx Biotec Ltd
HealthcareNSE: ONYX Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹73.62 Cr
Volatility
Moderate
P/E Ratio
-341.7
EBITDA
₹3.40 Cr
Return on Equity
8.91%
Debt to Equity
0.27
Book Value
₹30.56
52W High
₹51
52W Low
₹24.2
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Onyx Biotec Ltd insights
29 extracted metrics + investor summaries across FY22–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Weaknesses
2- Company has low interest coverage ratio.
- Company has a low return on equity of 6.49% over last 3 years.
Growth Rate
Revenue Growth
10.10% ↘
Net Income Growth
-116.40% ↘
Cash Flow Change
-6.58% ↘
ROE
-38.00% ↘
ROCE
1.02% ↗
EBITDA Margin (Avg.)
-73.36% ↘
Quarterly Results
| Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 23.89 | 29.86 | 30.15 | 31.8 | 34.59 | 34.88 |
| Expenses | 20.47 | 24.95 | 24.44 | 27.17 | 33.65 | 32.43 |
| Operating Profit | 3.42 | 4.91 | 5.71 | 4.63 | 0.94 | 2.45 |
| OPM % | 14.32% | 16.44% | 18.94% | 14.56% | 2.72% | 7.02% |
| Other Income | 0.04 | 0.09 | 0.99 | 0.18 | 0.24 | 0.21 |
| Interest | 0.83 | 1.27 | 1.36 | 0.62 | 0.55 | 0.66 |
| Depreciation | 0.73 | 1.14 | 1.53 | 1.51 | 1.56 | 1.49 |
| PBT | 1.9 | 2.59 | 3.81 | 2.68 | -0.93 | 0.51 |
| Tax % | 15.26% | 21.24% | 21.52% | 26.12% | -3.23% | -35.29% |
| Net Profit | 1.6 | 2.03 | 2.99 | 1.97 | -0.9 | 0.69 |
| EPS in Rs | 2.71 | 1.52 | 2.24 | 1.09 | -0.5 | 0.38 |
Profit & Loss
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 44.86 | 39.49 | 53.75 | 61.95 | 69.47 |
| Expenses | 39.09 | 34.99 | 45.36 | 51.57 | 66.07 |
| Operating Profit | 5.77 | 4.5 | 8.39 | 10.38 | 3.4 |
| OPM % | 12.86% | 11.4% | 15.61% | 16.76% | 4.89% |
| Other Income | 0.12 | 0.11 | 0.13 | 1.17 | 0.44 |
| Interest | 0.65 | 0.57 | 2.16 | 2.02 | 1.21 |
| Depreciation | 1.45 | 1.49 | 1.87 | 3.05 | 3.05 |
| PBT | 3.79 | 2.55 | 4.49 | 6.48 | -0.42 |
| Tax % | 11.61% | 27.45% | 19.15% | 23.46% | -50% |
| Net Profit | 3.35 | 1.84 | 3.63 | 4.95 | -0.21 |
| EPS in Rs | 5.68 | 3.12 | 2.72 | 2.73 | -0.12 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 5.9 | 5.9 | 13.32 | 18.13 | 18.13 |
| Reserves | 10.47 | 12.3 | 11.97 | 37.49 | 37.28 |
| Borrowings | 12.25 | 29.23 | 30.78 | 12.46 | 15.17 |
| Other Liabilities | 8.22 | 11.3 | 18.07 | 23.17 | 24.57 |
| Total Liabilities | 36.84 | 58.73 | 74.14 | 91.25 | 95.15 |
| Fixed Assets | 17.23 | 42.5 | 43.48 | 40.9 | 39.16 |
| CWIP | 4.02 | 0 | 0 | 0 | 3.68 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 15.59 | 16.23 | 30.66 | 50.35 | 52.31 |
| Total Assets | 36.84 | 58.73 | 74.14 | 91.25 | 95.15 |
Cash Flow
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Operating | 0.49 | 1.96 | 1.52 | 1.42 | -1.49 |
| Investing | -5.78 | -22.68 | -3.15 | 0.66 | -4.58 |
| Financing | 5.2 | 16.43 | 3.09 | 5.07 | 1.5 |
| Net Cash Flow | -0.09 | -4.3 | 1.46 | 7.15 | -4.57 |
| Free Cash Flow | -5.3 | -20.78 | -1.7 | 1.91 | -6.48 |
| CFO/OP | 8 | 44 | 18 | 14 | -44 |
Ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 68.51 | 46.95 | 104 | 119 | 144 |
| Inventory Days | 41.98 | 110 | 92.94 | 150 | 99.2 |
| Days Payable | 59.46 | 120 | 141 | 156 | 125 |
| Cash Conversion Cycle | 51.03 | 36.71 | 56.48 | 113 | 119 |
| Working Capital Days | 35.72 | -52.22 | 37.62 | 87.49 | 77.29 |
| ROCE % | — | 8.23% | 12.85% | 12.16% | 1.14% |
Documents
1
Corrigendum
4 Aug - VC Corporate Advisors Private Limited has Submitted to the Exchange a copy of corrigendum to the public announcement dated July24, 2026 for the attention of … 4 Aug - VC Corporate Advisors Private Limited has Submitted to the Exchange a copy of corrigendum to the public announcement dated July24, 2026 for the attention of …
2
Updates
31 Jul - Announcement text unreadable; key details cannot be determined. 31 Jul - Announcement text unreadable; key details cannot be determined.
3
Public Announcement-Open Offer
24 Jul - VC Corporate Advisors Pvt Ltd has submitted to the Exchange a copy of Public announcement under Regulations 3(1) and 4 Read with Regulations 13, 14 … 24 Jul - VC Corporate Advisors Pvt Ltd has submitted to the Exchange a copy of Public announcement under Regulations 3(1) and 4 Read with Regulations 13, 14 …
4
Certificate under SEBI (Depositories and Participants) Regulations, 2018
8 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026. 8 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026.
5
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
8 Jul - Onyx Biotec says corporate governance provisions don’t apply for quarter ended June 30, 2026. 8 Jul - Onyx Biotec says corporate governance provisions don’t apply for quarter ended June 30, 2026.
Frequently Asked Questions about Onyx Biotec Ltd
What does Onyx Biotec Ltd do?
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry
Syrup for India and overseas, through a
B2B business model[1]
Where is Onyx Biotec Ltd (ONYX) listed?
Onyx Biotec Ltd is listed on the Indian stock exchanges. It is listed on NSE: ONYX. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Onyx Biotec Ltd belong to?
Onyx Biotec Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Onyx Biotec Ltd?
Onyx Biotec Ltd has a market capitalisation of approximately ₹73.62 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Onyx Biotec Ltd?
The Price-to-Earnings (PE) ratio of Onyx Biotec Ltd is -341.70. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Onyx Biotec Ltd?
Over the past 52 weeks, Onyx Biotec Ltd has traded between a low of ₹24.2 and a high of ₹51. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Onyx Biotec Ltd?
Onyx Biotec Ltd has a Return on Equity (ROE) of 8.91%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Onyx Biotec Ltd on Tapetide?
On Tapetide, you can view Onyx Biotec Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas, through a B2B business model[1]